Ronald Blue Trust, Inc. Summit Therapeutics Inc. Transaction History
Ronald Blue Trust, Inc.
- $8.16 Billion
- Q4 2024
A detailed history of Ronald Blue Trust, Inc. transactions in Summit Therapeutics Inc. stock. As of the latest transaction made, Ronald Blue Trust, Inc. holds 371 shares of SMMT stock, worth $8,677. This represents 0.0% of its overall portfolio holdings.
Number of Shares
371Holding current value
$8,677% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding SMMT
# of Institutions
198Shares Held
75.9MCall Options Held
2.01MPut Options Held
2.84M-
Baker Bros. Advisors LP New York, NY24.4MShares$571 Million5.73% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.9MShares$256 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.9MShares$185 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD5.44MShares$127 Million0.01% of portfolio
-
State Street Corp Boston, MA3.47MShares$81.1 Million0.0% of portfolio
About Summit Therapeutics Inc.
- Ticker SMMT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 201,215,008
- Market Cap $4.71B
- Description
- Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...